Assembly Biosciences, Inc. (ASMB) Balance Sheet

The balance sheet trajectory shows a sharp inflection point in Q3 2025, where total assets jumped from $80.8M to $240.0M, indicating a major financing event. This influx of capital has dramatically improved the company's financial position, reducing leverage and extending its operational runway. However, the underlying business continues to generate substantial losses, as evidenced by the deeply negative retained earnings of -$845.0M, suggesting the strengthening is purely capital-driven rather than operationally generated.

The current ratio of 13.99 in Q2 2026 suggests ample short-term liquidity, but this is largely a function of the recent capital raise rather than operational cash generation. The significant quarterly swings in cash, such as the $36.0M increase from Q3 to Q4 2025 followed by a $26.2M decrease to Q2 2026, highlight the lumpy nature of collaboration payments and the high fixed-cost R&D burn. Investors should monitor the quarterly cash burn relative to the remaining balance to assess the true runway for clinical execution.

The equity composition reveals a stark contrast: while the paid-in capital has grown substantially, the retained earnings deficit has continued to widen, indicating that the company is not yet self-sustaining. This structure is typical for a clinical-stage biotech relying on equity markets to fund its pipeline. The recent capital infusion appears to have been a strategic move to secure a longer runway, but it also means that future value creation must be significant to justify the dilution to existing shareholders.